A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Clinical trial NCT07155187 · RECRUITING

Trial details

NCT number: NCT07155187
Sponsor: AbbVie
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer

Start date: 2025-12-10
Primary completion: 2030-09-01
Enrollment: 490

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.